左西孟旦对老年慢性心力衰竭患者的治疗效果观察和对血清NT-proBNP、ST2水平的影响  

Curative Effect Observation of Levosimendan on Elderly Patients with Chronic Heart Failure and Its Effect on Serum Nt-probnp and ST2 Levels

作　　者：王晓波 张珍[1] 邢艳秋[1] 刘春 WANG Xiao-bo;ZHANG Zhen;XING Yan-qiu;LIU Chun(Department of Geriatrics,Qilu Hospital of Shandong University,Jinan,Shandong 250012;Cardiology Department No.1,Jinan City The Fourth People's Hospital,Jinan,Shandong 250031)

机构地区：[1]山东大学齐鲁医院老年医学科,山东济南250012 [2]济南市第四人民医院心内一科,山东济南250031

出　　处：《智慧健康》2020年第24期193-194,196,共3页Smart Healthcare

基　　金：国家自然科学基金面上项目(项目编号:81570356);国家自然科学基金青年项目(项目编号:81700725);山东省重点研发计划项目(项目编号:2017GSF218014,2017GSF218101);山东省自然科学基金资助项目(项目编号:ZR2017BH003)。

摘　　要：目的探讨左西孟旦对老年慢性心力衰竭患者的治疗效果和对血清NT-pro BNP及ST2水平的影响。方法选择2019年1月至2019年12月之间在山东大学齐鲁医院老年医学科就诊的年龄大于60岁的慢性心力衰竭患者80例为研究对象,按治疗方式不同,随机分为对照组和联合组各40例。对照组患者给予心血管临床常规抗心衰治疗方法,联合组则同时联合左西孟旦治疗。治疗效果以临床症状改善情况评价。结果两组患者经治疗后,对照组患者中显效7例,有效18例,无效15例,临床总有效率为62.5%;联合组患者中显效24例,有效9例,无效7例,临床总有效率为89.2%联合组显著高于对照组的(P<0.05)。对照组、联合组治疗前LVEF均<治疗后,治疗前NT-proBNP均>治疗后,P<0.05,有统计学意义。两组比较,联合组治疗后LVEF(39.94±6.43)%高于对照组治疗后LVEF(36.54±7.13)%;联合组治疗后NT-proBNP(5397.76±1013.40)pg/mL低于对照组治疗后NT-proBNP(5904.23±1042.35)pg/mL,P<0.05,有统计学意义。治疗后的ST2,联合组明显低于对照组,P<0.05,有统计学意义。结论左西孟旦可显著改善老年心力衰竭患者的临床症状,提高临床有效率,显著降低血清sST2和NT-ProBNP水平显著降低,且用药安全。Objective to investigate curative effect of levosimendan on elderly patients with chronic heart failure and effect on serum NT-pro BNP and ST2 levels.Methods choose 80 cases chronic heart failure patients over 60 in geriatrics department,Qilu Hospital of Shandong University from January 2019 and December 2019 as research objects.According to different treatment methods,divide them into control group and combined group randomly,40 cases in each group.Control group was treated with routine cardiovascular clinical anti-heart failure treatments,and combination group with levosimendan at the same time.Evaluated treatment effect based on improvement of clinical symptoms.Results after treatment between two groups,7 cases were markedly effective,18 cases effective,and 15 cases ineffective in control group,with total clinical effective rate of 62.5%;in combination group,24 cases were markedly effective,9 cases effective,and 7 cases ineffective.Effective rate of 89.2%in combined group was significantly higher than control group(P<0.05).LVEF before treatment in control group and combination group was less than after treatment,and NT-proBNP before treatment was more than after treatment,P<0.05,which was statistically significant.LVEF(39.94±6.43)%of combined group after treatment was higher than(36.54±7.13)%after treatment of control group;NT-proBNP(5397.76±1013.40)pg/ml after treatment in combined group was lower than NT-proBNP(5904.23±1042.35)pg/ml in control group after treatment,P<0.05,with statistical significance.ST2 after treatment in combination group was significantly lower than control group,P<0.05,which was statistically significant.Conclusion levosimendan can improve clinical symptoms of elderly patients with heart failure significantly,increase clinical effectiveness,reduce serum sST2 and NT-ProBNP levels significantly,which is safe for application.

关 键 词：氨基末端脑利钠肽前体 左西孟旦 ST2 心力衰竭 

分 类 号：R541.6[医药卫生—心血管疾病]